IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 12:30 PM ESTCompany ParticipantsShaun Bagai - ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

As we look to 2026, there's a bright future for well-governed healthcare information to advance artificial intelligence ...

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

This article collection focuses on the rapidly emerging utilization of artificial intelligence (AI) to revolutionize cardiovascular disease prediction and ...

Data integrity is the backbone of every clinical trial, ensuring that research truly benefits patients and advances medical science. When information is accurate, complete, and transparent, doctors ...

RNA-based therapeutics face challenges in bioanalysis, with experts recommending strategies to improve LC–MS performance and standardize ADME and DMPK practices. GLP-1 therapies require careful ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

Objective To develop prediction models for short-term outcomes following a first acute myocardial infarction (AMI) event (index) or for past AMI events (prevalent) in a national primary care cohort.

The Centers for Medicare & Medicaid Services (“CMS”), through the CMS Innovation Center (“CMMI”), has announced the ACCESS Model—Advancing ...

The technology is designed to help thousands of diabetic and hypertensive patients achieve control over their conditions, ...

According to a filing with the U.S. Securities and Exchange Commission dated November 14, Commodore Capital LP disclosed a new stake in Amylyx Pharmaceuticals (NASDAQ:AMLX). The fund reported ...